Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.05 USD
+0.16 (5.54%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.06 +0.01 (0.33%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.05 USD
+0.16 (5.54%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.06 +0.01 (0.33%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Zacks News
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
by Zacks Equity Research
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.
Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study
by Zacks Equity Research
Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
by Zacks Equity Research
Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
by Zacks Equity Research
Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.
Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%
by Zacks Equity Research
Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
by Zacks Equity Research
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock
by Zacks Equity Research
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
by Zacks Equity Research
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
by Zacks Equity Research
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
by Zacks Equity Research
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up
by Zacks Equity Research
Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.
Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
by Zacks Equity Research
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
Here's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price Strength
by Zacks Equity Research
ANIXA BIOSCIENCES INC (ANIX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"
by Zacks Equity Research
ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
by Zacks Equity Research
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
by Zacks Equity Research
The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.
Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.